Company intelligence / Profile preview

Delagrave Life Sciences

Sudbury, Massachusetts, United Stateslinkedin.com ↗

Ownership: Private
Employees: ~1
Development stage: Other

Overview

Delagrave Life Sciences is a boutique biotechnology research and consulting firm founded in 2023 by Dr. Simon Delagrave, an experienced R&D executive with deep expertise in virology, vaccines, gene therapy, and infectious disease drug development. The company provides strategic advisory services to biotechs, venture creation firms, hospital networks’ gene/cell therapy institutes, and early-stage companies. It does not appear to have its own therapeutic pipeline or products in clinical trials as of June 2025.

Therapeutic areas: Infectious Diseases
Modalities: VaccineGene therapy (consulting/expertise)
Industry: Drug Discovery Services

Beyond the preview

Go deeper on Delagrave Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Delagrave Life Sciences.

Explore the full profile